151 related articles for article (PubMed ID: 23881922)
1. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
2.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
3. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
Lee SH; Hwang HK; Lee WJ; Kang CM
Cell Oncol (Dordr); 2021 Dec; 44(6):1363-1371. PubMed ID: 34791637
[TBL] [Abstract][Full Text] [Related]
4. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
[TBL] [Abstract][Full Text] [Related]
5. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.
Zhang J; Ye Y; Chang DW; Lin SH; Huang M; Tannir NM; Matin S; Karam JA; Wood CG; Chen ZN; Wu X
Am J Pathol; 2018 Nov; 188(11):2487-2496. PubMed ID: 30201497
[TBL] [Abstract][Full Text] [Related]
6. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.
Haake SM; Brooks SA; Welsh E; Fulp WJ; Chen DT; Dhillon J; Haura E; Sexton W; Spiess PE; Pow-Sang J; Rathmell WK; Fishman M
Urol Oncol; 2016 Mar; 34(3):122.e1-7. PubMed ID: 26546482
[TBL] [Abstract][Full Text] [Related]
7. Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.
Winter S; Fisel P; Büttner F; Rausch S; D'Amico D; Hennenlotter J; Kruck S; Nies AT; Stenzl A; Junker K; Scharpf M; Hofmann U; van der Kuip H; Fend F; Ott G; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E
Sci Rep; 2016 Jul; 6():29930. PubMed ID: 27435027
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
[TBL] [Abstract][Full Text] [Related]
9. Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma.
Park CK; Heo J; Ham WS; Choi YD; Shin SJ; Cho NH
Cancer Res Treat; 2021 Oct; 53(4):1174-1183. PubMed ID: 33735560
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis.
Yuan C; Zhang J; Lou J; Wang S; Jiang Y; Wu F; Wang S
Bioengineered; 2021 Dec; 12(1):3850-3863. PubMed ID: 34269158
[TBL] [Abstract][Full Text] [Related]
11. MCT4 and CD147 colocalize with MMP14 in invadopodia and support matrix degradation and invasion by breast cancer cells.
Meng S; Sørensen EE; Ponniah M; Thorlacius-Ussing J; Crouigneau R; Larsen T; Borre MT; Willumsen N; Flinck M; Pedersen SF
J Cell Sci; 2024 Apr; 137(8):. PubMed ID: 38661040
[TBL] [Abstract][Full Text] [Related]
12. FOXD1 regulates cell division in clear cell renal cell carcinoma.
Bond KH; Fetting JL; Lary CW; Emery IF; Oxburgh L
BMC Cancer; 2021 Mar; 21(1):312. PubMed ID: 33761914
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
Lin YL; Wang YL; Fu XL; Ma JG
Med Sci Monit; 2014 Nov; 20():2380-5. PubMed ID: 25416427
[TBL] [Abstract][Full Text] [Related]
14. Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal Cancers.
Loginov VI; Dmitriev AA; Senchenko VN; Pronina IV; Khodyrev DS; Kudryavtseva AV; Krasnov GS; Gerashchenko GV; Chashchina LI; Kazubskaya TP; Kondratieva TT; Lerman MI; Angeloni D; Braga EA; Kashuba VI
PLoS One; 2015; 10(5):e0123369. PubMed ID: 25961819
[TBL] [Abstract][Full Text] [Related]
15. A novel DNA methylation signature revealed GDF6 and RCC1 as potential prognostic biomarkers correlated with cell proliferation in clear cell renal cell carcinoma.
Xu Z; Wu Y; Zhao G; Jin B; Jiang P
Mol Biol Rep; 2023 Dec; 51(1):16. PubMed ID: 38087057
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylation-Mediated Upregulation of NFE2L3 Promotes Malignant Phenotypes of Clear Cell Renal Cell Carcinoma Cells.
Hou X; Liao Q; Wu Y; Wang L; Zhao J; Liao X
Mol Biotechnol; 2024 Feb; 66(2):198-207. PubMed ID: 37071304
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between methylation of interferon regulatory factor 6 gene promoter in renal tissues and overall survival of patients with Kidney renal clear cell carcinoma].
Zhang J; Chen C; Wei Y; Chen L; Shao P; Xu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Feb; 41(2):150-156. PubMed ID: 38311552
[TBL] [Abstract][Full Text] [Related]
18. A systemic analysis of monocarboxylate transporters in ovarian cancer and possible therapeutic interventions.
Chatterjee P; Bhowmik D; Roy SS
Channels (Austin); 2023 Dec; 17(1):2273008. PubMed ID: 37934721
[TBL] [Abstract][Full Text] [Related]
19. CD2AP is a potential prognostic biomarker of renal clear cell carcinoma.
Chen C; Xu J; Zhang JX; Chen LY; Wei YA; Zhang WM; Shao PF; Xu HG
Cancer Med; 2024 Feb; 13(4):e7055. PubMed ID: 38457255
[TBL] [Abstract][Full Text] [Related]
20. Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.
Bhagat TD; Zou Y; Huang S; Park J; Palmer MB; Hu C; Li W; Shenoy N; Giricz O; Choudhary G; Yu Y; Ko YA; Izquierdo MC; Park AS; Vallumsetla N; Laurence R; Lopez R; Suzuki M; Pullman J; Kaner J; Gartrell B; Hakimi AA; Greally JM; Patel B; Benhadji K; Pradhan K; Verma A; Susztak K
J Biol Chem; 2017 Jan; 292(3):837-846. PubMed ID: 27909050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
